A Phase 1, Multicenter, Open-label, Dose Escalation Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas
Latest Information Update: 12 Jun 2024
At a glance
- Drugs Berubicin (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; First in man
- Sponsors WPD Pharmaceuticals
Most Recent Events
- 03 Jun 2024 Planned End Date changed from 1 Dec 2025 to 30 Dec 2023.
- 03 Jun 2024 Planned primary completion date changed from 1 Dec 2025 to 30 Dec 2023.
- 03 Jun 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Business decision)